Literature DB >> 35023430

Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines.

Hunter McFall-Boegeman1,2, Xuefei Huang1,2,3.   

Abstract

INTRODUCTION: Vaccination can be effective defense against many infectious agents and the corresponding diseases. Discoveries elucidating the mechanisms of the immune system have given hopes to developing vaccines against diseases recalcitrant to current treatment/prevention strategies. One such finding is the ability of immunogenic biological nanoparticles to powerfully boost the immunogenicity of poorer antigens conjugated to them with virus-like particle (VLP)-based vaccines as a key example. VLPs take advantage of the well-defined molecular structures associated with sub-unit vaccines and the immunostimulatory nature of conjugate vaccines. AREAS COVERED: In this review, we will discuss how advances in understanding the immune system can inform VLP-based vaccine design and how VLP-based vaccines have uncovered underlying mechanisms in the immune system. EXPERT OPINION: As our understanding of mechanisms underlying the immune system increases, that knowledge should inform our vaccine design. Testing of proof-of-concept vaccines in the lab should seek to elucidate the underlying mechanisms of immune responses. The integration of these approaches will allow for VLP-based vaccines to live up to their promise as a powerful plug-and-play platform for next-generation vaccine development.

Entities:  

Keywords:  Biomacromolecules; conjugate vaccines; mechanism of immune response; nanoparticles; virus-like particles

Mesh:

Substances:

Year:  2022        PMID: 35023430      PMCID: PMC8960355          DOI: 10.1080/14760584.2022.2029415

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  173 in total

1.  Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway.

Authors:  Stephanie J Win; Vernon K Ward; P Rod Dunbar; Sarah L Young; Margaret A Baird
Journal:  Immunol Cell Biol       Date:  2011-01-11       Impact factor: 5.126

Review 2.  Dendritic cells in cancer immunology and immunotherapy.

Authors:  Stefanie K Wculek; Francisco J Cueto; Adriana M Mujal; Ignacio Melero; Matthew F Krummel; David Sancho
Journal:  Nat Rev Immunol       Date:  2019-08-29       Impact factor: 53.106

3.  Antibody Response against Cowpea Mosaic Viral Nanoparticles Improves In Situ Vaccine Efficacy in Ovarian Cancer.

Authors:  Sourabh Shukla; Chao Wang; Veronique Beiss; Nicole F Steinmetz
Journal:  ACS Nano       Date:  2020-03-05       Impact factor: 15.881

Review 4.  The tipping points in the initiation of B cell signalling: how small changes make big differences.

Authors:  Susan K Pierce; Wanli Liu
Journal:  Nat Rev Immunol       Date:  2010-10-11       Impact factor: 53.106

5.  Engineering the PP7 Virus Capsid as a Peptide Display Platform.

Authors:  Liangjun Zhao; Mykhailo Kopylov; Clinton S Potter; Bridget Carragher; M G Finn
Journal:  ACS Nano       Date:  2019-03-26       Impact factor: 15.881

6.  Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model.

Authors:  Bryce Chackerian; Marisa R Durfee; John T Schiller
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

7.  Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer.

Authors:  Jinming Li; Yanli Sun; Tingting Jia; Rui Zhang; Kuo Zhang; Lunan Wang
Journal:  Int J Cancer       Date:  2013-10-08       Impact factor: 7.396

8.  Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications.

Authors:  Mark L Smith; John A Lindbo; Stephan Dillard-Telm; Paul M Brosio; Amanda B Lasnik; Alison A McCormick; Long V Nguyen; Kenneth E Palmer
Journal:  Virology       Date:  2006-02-08       Impact factor: 3.616

9.  Induction of Antiviral Immune Response through Recognition of the Repeating Subunit Pattern of Viral Capsids Is Toll-Like Receptor 2 Dependent.

Authors:  Kelly M Shepardson; Benjamin Schwarz; Kyle Larson; Rachelle V Morton; John Avera; Kimberly McCoy; Alayna Caffrey; Ann Harmsen; Trevor Douglas; Agnieszka Rynda-Apple
Journal:  MBio       Date:  2017-11-14       Impact factor: 7.867

10.  Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer.

Authors:  Archana Monie; Chien-Fu Hung; Richard Roden; T-C Wu
Journal:  Biologics       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.